Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.67 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869208 | 0.90 | SIRT1 (0.79) | SIRT1MAPKAPK2SIRT2SIRT3BAZ2B | |
| SCHEMBL4905956 | 0.90 | SIRT1 (0.83) | SIRT1HTR1BKMT2ASIRT2SIRT3 | |
| SCHEMBL11680029 | 0.88 | SIRT1 (0.77) | SIRT1MAPKAPK2SIRT2SIRT3BAZ2B | |
| SCHEMBL11680034 | 0.88 | SIRT1 (0.77) | SIRT1MAPKAPK2SIRT2SIRT3BAZ2B | |
| Dimethylamine SCHEMBL11683926 | 0.85 | SIRT1 (0.72) | SIRT1MAPKAPK2BAZ2B | |
| SCHEMBL11839880 | 0.85 | HTR1B (0.50) | SIRT1HTR1BKMT2AHTR1AHTR1D | |
| SCHEMBL4899304 | 0.84 | HTR1B (0.52) | SIRT1HTR1BMAPKAPK2KMT2ABAZ2B | |
| SCHEMBL4895910 | 0.84 | HTR1B (0.52) | SIRT1HTR1BMAPKAPK2KMT2ABAZ2B | |
| SCHEMBL11845531 | 0.84 | SIRT1 (0.55) | SIRT1HTR1BKMT2ASIRT2BAZ2B | |
| SCHEMBL4897652 | 0.84 | HTR1B (0.52) | SIRT1HTR1BMAPKAPK2KMT2ABAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081910-A1 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2008-04-03 | — | — | US | disclosed |
| EP-1856126-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7297704-B2 | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060205759-A1 | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives | WYETH (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006089053-A2 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-3948939-A | 9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids | STERLING DRUG INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205759-A1 | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives | TPH1, TPH2, HTR2C | SIRT1 389/4885HTR1B 19/4885MAPKAPK2 2878/4885 |
| US-20080081910-A1 | CYCLOALKYLFUSED INDOLE, BENZOTHIOPHENE, BENZOFURAN AND INDENE DERIVATIVES | TPH1, TPH2, HTR2C | SIRT1 389/4885HTR1B 19/4885MAPKAPK2 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.